20 results
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Prospectus supplement
6:07am
an innovative and well-tolerated drug for proton therapy sensitization.
Execute a disciplined business development strategy to strengthen our portfolio of product
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
24 Aug 23
Prospectus supplement
2:00pm
technology offers a major opportunity for Shuttle Pharma to strive to develop an innovative and well-tolerated drug for proton therapy sensitization … the FDA to utilize innovative and flexible approaches to the assessment of product candidates under accelerated approval. The law required the FDA
8-K
EX-99.1
SHPH
Shuttle Pharmaceuticals Holdings Inc
15 Aug 23
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
9:00am
with funding from NIH small business innovative (SBIR) research contracts over the past several years, particularly for our predictive biomarker
DRS
edaijohhxm1
29 Sep 22
Draft registration statement
12:00am
424B4
5o2ek9m67cw7xb1
31 Aug 22
Prospectus supplement with pricing info
6:16am
S-1
nvn2rrqwy6d0jzv oh81
3 Jun 22
IPO registration
5:32pm
S-1
EX-10.31
j576w ijvzhgvqd
3 Jun 22
IPO registration
5:32pm
DRS/A
ehtjy3e 3th
26 Apr 22
Draft registration statement (amended)
12:00am
DRS
iukhs0 0qm5j
16 Sep 19
Draft registration statement
12:00am
- Prev
- 1
- Next